The French Financial Advice Market 2005: Industry Research Report

The French Financial Advice Market 2005

Published Date: March 2005

Published By: Datamonitor

Page Count: 33

Order Code: R313-8401

Questions About This Report

E-mail a Colleague

Printable Page

Fax Your Order

Description

Table of Contents

Search Inside
this Report

Similar
Products

TABLE OF CONTENTS
Executive summary 5
Introduction 6
Mechanisms of drug withdrawals 6
Recent withdrawals 9
Baycol (cerivastatin) 9
Rezulin (troglitazone) 12
Posicor (mibefradil) 14
The impact of drug withdrawals 17
Changes to the drug approval process 17
Safety investigations 18
Consequences for pharmaceutical companies 20
The future for cardiovascular drug approvals 21
Conclusion 22
Case study: Baycol (cerivastatin) 23
What will be the effect on other statins? 24
Big blow for Bayer but low impact on global statin market 24
Reactions in the US to the withdrawal of Baycol 27
EU review of statins 28
The future for Baycol 29

Appendix 31
Datamonitor's Cardiovascular Business Unit 31
Bibliography 31
Association and company links 32
Further reading 33

Similar Products

• Financial Planners and Investment Advisors

Published Oct 2008 by First Research, Inc.

• Open-End Investment Funds in the US - Industry Risk Rating Report

Published Oct 2008 by IBISWorld

• Financial Planning & Advice in the US - Industry Risk Rating Report

Published Oct 2008 by IBISWorld

• Plimsoll Analysis- Independent Financial Advisors (UK)

Published Oct 2008 by Plimsoll Publishing Ltd.

• Aging Population in the Western World - Investment Opportunities

Published Sep 2008 by Frost & Sullivan

• Financial Planning & Investment Advice in Australia - Industry Risk Rating Report